TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06517459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance
Description: The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting,4 and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems.
Study: NCT05412316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: Short-wave diathermy
Description: The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
Study: NCT06004258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painless Vaccination
Description: Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing
Study: NCT05172323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DCT-scan
Description: A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Angiography guided PCI
Description: Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
Study: NCT05957016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CIETAI-R
Description: 1. phase I: (1) Chemo-Immulo-embolization via Tumor Arterial, CIETAI: DSA guided tumor artery infusion of oxaliplatin 130 mg/m2+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. phase II: Chemoradiotherapy: IMRT：45Gy/25f/5w+capecitabine 1000，po. Bid d1-14, q3w Tirelizumab)200mg ivggt, d1, q3w
Study: NCT04953273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigitrauma
Description: Case management algorithm using early phone contact
Study: NCT05841303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit C
Description: Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: injectable PRF
Description: 5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins \[Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
Study: NCT05803928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib + anti-PD-1 antibodies
Description: A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: radiofrequency ablation or microwave ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: radiofrequency ablation or microwave ablation
Study: NCT04681066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CM-4620 Injectable Emulsion or CM-4620-IE
Description: Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CM-4620 Injectable Emulsion or CM-4620-IE
Description: Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CM-4620 Injectable Emulsion or CM-4620-IE
Description: Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
Study: NCT06300814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise group
Description: A video containing the progressive relaxation exercise was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group to whom progressive relaxation exercise would be applied, and the children applied progressive relaxation exercise (15 minutes of progressive relaxation exercise before bedtime for a total of 4 weeks, 5 days a week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music recital group
Description: The link of the music recital (link) was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group, where the music concert will be applied, and the children listened to it (music concert was applied for 15 minutes before going to bed, 5 days a week for a total of 4 weeks).
Study: NCT05924854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~1. Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675
Study: NCT04326465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage
Description: Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
Study: NCT06407882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conductive Exercises
Description: Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
Study: NCT06116084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ericksonian Hypnosis
Description: An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
Study: NCT05891366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL0921
Description: Investigational product WAL0921
Study: NCT06057441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory noise stimulation
Description: Auditory white noise stimulation delivered at 78dB through earphones

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual noise stimulation
Description: Visual white pixel noise stimulation, backgound pixel noise visible at computer screen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual noise stimulation
Description: Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
Study: NCT05477498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
Study: NCT05604248

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
Study: NCT05891366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product
Study: NCT06459193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Trimetazidine 35 mg tab once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT06349577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-pulsatile blood flow
Description: Non-pulsatile blood flow generated by constant centrifugal pump flow rate during cardiopulmonary bypass

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile blood flow
Description: Pulsatile blood flow generated by variable centrifugal pump flow rate during cardiopulmonary bypass
Study: NCT05880355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: Oral inhibitor of NLRP3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo
Study: NCT00051090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Administered orally twice daily in doses of 300 mg
Study: NCT05833555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MH task-sharing training
Description: Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MH task-sharing training
Description: Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MH task-sharing training
Description: Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision
Description: Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision
Description: Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Intervention
Description: To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
Study: NCT06409611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)
Study: NCT05955872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.
Study: NCT05968625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoformed retainers
Description: conventional thermoformed retainers fabricated on stone models.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed retainers
Description: 3D-printed retainers fabricated directly by DLP printer.
Study: NCT05146037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 and saline flushing
Description: TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline flushing
Description: TAVI valves will be flushed with saline only as per IFU.
Study: NCT05452317

Intervention type: OTHER
Intervention: Chronic active AMR group
Description: Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.

Intervention type: OTHER
Intervention: Non-Chronic active AMR group
Description: Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
Study: NCT06391580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly-L-lactin Acid (PLLA) Based Facial Injectable
Description: Poly-L-lactin Acid (PLLA) Based Facial Injectable
Study: NCT04798222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
Study: NCT05196204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk-oriented task training combined with functional electrical stimulation
Description: Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk-oriented task training alone
Description: The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
Study: NCT04981548

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention